By Marc Navarro Gonzalez 
 

Bayer AG (BAYN.XE) has received a warning letter from the U.S. Food and Drug Administration regarding drug manufacturing practices at the company's supply center in Leverkusen, Germany.

The company said Wednesday that the letter was sent after a routine inspection of the Leverkusen center in January, and that it has been carrying out corrective measures since then.

"Bayer is fully committed to diligently addressing the FDA observations and to continue the corresponding implementation of necessary corrective actions," the company said in a statement.

The ongoing remediation and modernization works at the site are likely to result in temporary supply limitations, Bayer said. It said it will report the impact of these measures in its upcoming guidance release on Feb. 28.

The company said that product release-and-distribution operations continue at the Leverkusen site and that it has no evidence that patient safety has been put at risk.

Write to Marc Navarro Gonzalez at marc.navarrogonzalez@dowjones.com

(END) Dow Jones Newswires

February 14, 2018 09:46 ET (14:46 GMT)